Phase 1 Trial of Atezolizumab Plus Trimodal Therapy in Patients With Localized Muscle-Invasive Bladder Cancer

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

Joaquim Bellmunt, Ronald de Wit, David J. Vaughn et al. · New England Journal of Medicine · 2017 · 3.3K citations · Full text

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

Thomas Powles, Joseph P. Eder, Gregg Fine et al. · Nature · 2014 · 2.4K citations

Urology, Oncology, Genitourinary Cancer +5

Dose-limiting Urinary Toxicity With Pembrolizumab Combined With Weekly Hypofractionated Radiation Therapy in Bladder Cancer

Alison Tree, Kelly Jones, S. Hafeez et al. · International Journal of Radiation Oncology*Biology*Physics · 2018 · 96 citations · Full text

Urology, Radiation Medicine, Rectal Perforation +13

Hypofractionated Intensity Modulated Radiation Therapy in Combined Modality Treatment for Bladder Preservation in Elderly Patients With Invasive Bladder Cancer

Guy‐Anne Turgeon, Luís Souhami, Fabio Cury et al. · International Journal of Radiation Oncology*Biology*Physics · 2014 · 77 citations

Urology, Surgical Oncology, Radiation Medicine +8

PD-1/PD-L1 Immune Checkpoint Inhibition with Radiation in Bladder Cancer: <i>In Situ</i> and Abscopal Effects

Alexis Rompré‐Brodeur, Surashri Shinde-Jadhav, Mina Ayoub et al. · Molecular Cancer Therapeutics · 2019 · 50 citations